Ticker

REC.MI

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceuticals in Italy and internationally. It operates through Specialty and Primary Care and Rare Diseases segments. The company's product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS for the treatment of cystine crystal deposits in the cornea. It also develops CARBAGLU for hyperammonemia due to NAGS deficiency; QARZIBA, an apeiron for the treatment of high-risk neuroblastoma patients with a partial response at the chemotherapeutical through myeloablative therapy and stem cell transplantation, and relapsed or refractory neuroblastoma; and FOTIVDA, an oral inhibitor first-line treatment of renal cell carcinoma. In addition, the company offers SYLVANT for the treatment of idiopathic multicentric castleman diseases; REAGILA for Schizophrenia; and ELIGARD for hormone-dependent prostate cancer, as well as CAPHOSOL, a medical device for treatment electrolyte supersaturated of oral mucositis due to chemo and radiation therapy. Recordati Industria Chimica e Farmaceutica S.p.A. was founded in 1926 and is headquartered in Milan, Italy. Recordati Industria Chimica e Farmaceutica S.p.A. is a subsidiary of Rossini S.à R.L.